

Callitas Health Inc.

09:57 26 Feb 2019

Callitas Health strikes deal with pregnancy test maker to distribute its co-branded ToConceive gel

Callitas Health Inc (CSE:LILY) (OTCMKTS:WKULF) announced Tuesday that it had cemented a new partnership with NFI Consumer Healthcare's flagship e.p.t, over-the-counter pregnancy test kit brand.

The top brand established in 1977 introduced one of the first over-the-counter home pregnancy test kits in North America.

"ToConceive, our clinically proven fertility lubricant, is a perfect cobranding fit with e.p.t. pregnancy test kits, a category leader in the women's OTC health market," said Callitas Health CEO James Thompson. "e.p.t.'s brand recognition in the space will help our company build awareness for the fantastic impact ToConceive can have on couples trying to get pregnant."

READ: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs

Cincinnati-based health and wellness company Callitas Health's ToConceive was developed by Thompson's father, Dr Ronald Thompson, a well-known gynecologic surgeon and infertility specialist with nearly three dozen patents. It was based on the science behind the 2010 Nobel Prize in Medicine for in vitro fertilization (IVF) and sperm capacitation.

It's FDA-cleared and clinically proven to increase a woman's own natural conception lubrication, called transudate.

The partnership between NFI and Callitas will include promotional opportunities in stores, product samples and new product inclusion at major food, drug and mass retailers in the US.

"After purchasing EPT in 2017, our group began working on potential line extensions for the brand that would emerge it from only being a pregnancy test brand to becoming part of the complete family planning process," said Benjamin Blessing, executive vice president of sales and marketing at NFI Consumer Products.

"Developing a packaging concept that included the ToConceive product just made sense to us," Blessing said. "This is a brand completely devoted to helping women fulfill their desire to become pregnant. We are pleased to have a product that may facilitate a long-anticipated and life-changing pregnancy."

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Price: \$0.11

Market Cap: \$3.62 m

Share Information

Code: LILY

Listing: CSE

52 week	High	Low
	0.175	0.05

Sector: Pharma & Biotech

Website: www.callitas.com

Company Synopsis:

Founded on Midwest values, our Cincinnati-based company is people-focused, always looking for ways to benefit our customers, shareholders, and employees. Our company was built on strong work ethic, honesty, and a desire to help others. Our number one goal is helping people by bringing products to market that improve quality of life.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts

journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc. named herein, including the promotion by the Company of Callitas Health Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).